Skip to main
SWAV
SWAV logo

Shockwave Medical (SWAV) Stock Forecast & Price Target

Shockwave Medical (SWAV) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 23%
Hold 46%
Sell 8%
Strong Sell 0%

Bulls say

Shockwave Medical is positioned for long-term growth with its innovative technology and strong gross margin of 86.8%. The company's recent growth in coronary sales of 46%, driven by increased vessel bed penetration and potential pipeline initiatives, further supports a positive outlook for sustained double-digit revenue growth. This, combined with the potential for reimbursement upside and expansion into the BTK market, makes Shockwave Medical a promising med tech growth company.

Bears say

Shockwave Medical is facing potential challenges in their outpatient coronary IVL reimbursement and experienced a decline in operating margin. Furthermore, the company's recent acquisition of Neovasc may continue to impact them negatively, leading to lowered revenue estimates. As a result, our analyst believes that Shockwave Medical's financial performance may continue to struggle, leading to a negative outlook for their stock.

Shockwave Medical (SWAV) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 23% recommend Buy, 46% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shockwave Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shockwave Medical (SWAV) Forecast

Analysts have given Shockwave Medical (SWAV) a Buy based on their latest research and market trends.

According to 13 analysts, Shockwave Medical (SWAV) has a Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $280.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $280.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shockwave Medical (SWAV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.